Patterns of Relapse in Small Cell Lung Cancer: Competing Risks of Thoracic versus CNS Relapse

Introduction: Treatment algorithms for small cell lung cancer (SCLC) are determined largely by the Veterans Affairs Lung Cancer Staging Group (VALCSG) staging (limited (LS) versus extensive (ES) stage). Relapse occurs frequently; however, patterns of relapse, in particular the competing risk of thor...

Full description

Bibliographic Details
Main Authors: Peter M. Ellis, Anand Swaminath, Gregory R. Pond
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Current Oncology
Subjects:
Online Access:https://www.mdpi.com/1718-7729/28/4/243
_version_ 1797520729460178944
author Peter M. Ellis
Anand Swaminath
Gregory R. Pond
author_facet Peter M. Ellis
Anand Swaminath
Gregory R. Pond
author_sort Peter M. Ellis
collection DOAJ
description Introduction: Treatment algorithms for small cell lung cancer (SCLC) are determined largely by the Veterans Affairs Lung Cancer Staging Group (VALCSG) staging (limited (LS) versus extensive (ES) stage). Relapse occurs frequently; however, patterns of relapse, in particular the competing risk of thoracic and central nervous system relapse, are not well described. This study describes patterns of relapse in SCLC patients treated at a large tertiary institution in Ontario, Canada. Materials and Methods: A retrospective cohort of SCLC patients treated at the Juravinski Cancer Centre was reviewed. Data were abstracted from the medical record on demographic, disease, treatment and outcome variables. The primary outcome was a description of the patterns of relapse stratified by disease stage. Multivariate analysis was performed to identify prognostic variables for thoracic and CNS relapse. Results: Two hundred and twenty nine patients were treated during the study period (LS—83, ES—146). Relapse occurred in the majority of patients (isolated thoracic—28%, isolated CNS—9%, extrathoracic—9%, thoracic/extrathoracic—14%, systemic and CNS—13%). The median OS was consistent with published data (LS—21.8 months, ES—8.9 months). ES disease and elevated LDH were prognostic for increased thoracic relapse, whereas poor PS and older age were prognostic for lower central nervous system (CNS) relapse. Discussion: Thoracic relapse and CNS relapse represent competing risks for patients with SCLC. Decisions about incorporating thoracic or CNS radiation are complex. More research is needed to incorporate performance status and LDH into treatment algorithms.
first_indexed 2024-03-10T08:00:45Z
format Article
id doaj.art-1c290a2ebadc423cb5018d287091d06a
institution Directory Open Access Journal
issn 1198-0052
1718-7729
language English
last_indexed 2024-03-10T08:00:45Z
publishDate 2021-07-01
publisher MDPI AG
record_format Article
series Current Oncology
spelling doaj.art-1c290a2ebadc423cb5018d287091d06a2023-11-22T11:28:21ZengMDPI AGCurrent Oncology1198-00521718-77292021-07-012842778278810.3390/curroncol28040243Patterns of Relapse in Small Cell Lung Cancer: Competing Risks of Thoracic versus CNS RelapsePeter M. Ellis0Anand Swaminath1Gregory R. Pond2Department of Oncology, McMaster University, Main St W, Hamilton, ON L8S 4L8, CanadaDepartment of Oncology, McMaster University, Main St W, Hamilton, ON L8S 4L8, CanadaJuravinski Cancer Centre, Division of Medical Oncology, 699 Concession St, Hamilton, ON L8V 5C2, CanadaIntroduction: Treatment algorithms for small cell lung cancer (SCLC) are determined largely by the Veterans Affairs Lung Cancer Staging Group (VALCSG) staging (limited (LS) versus extensive (ES) stage). Relapse occurs frequently; however, patterns of relapse, in particular the competing risk of thoracic and central nervous system relapse, are not well described. This study describes patterns of relapse in SCLC patients treated at a large tertiary institution in Ontario, Canada. Materials and Methods: A retrospective cohort of SCLC patients treated at the Juravinski Cancer Centre was reviewed. Data were abstracted from the medical record on demographic, disease, treatment and outcome variables. The primary outcome was a description of the patterns of relapse stratified by disease stage. Multivariate analysis was performed to identify prognostic variables for thoracic and CNS relapse. Results: Two hundred and twenty nine patients were treated during the study period (LS—83, ES—146). Relapse occurred in the majority of patients (isolated thoracic—28%, isolated CNS—9%, extrathoracic—9%, thoracic/extrathoracic—14%, systemic and CNS—13%). The median OS was consistent with published data (LS—21.8 months, ES—8.9 months). ES disease and elevated LDH were prognostic for increased thoracic relapse, whereas poor PS and older age were prognostic for lower central nervous system (CNS) relapse. Discussion: Thoracic relapse and CNS relapse represent competing risks for patients with SCLC. Decisions about incorporating thoracic or CNS radiation are complex. More research is needed to incorporate performance status and LDH into treatment algorithms.https://www.mdpi.com/1718-7729/28/4/243small cell lung cancerrecurrent diseasehealth outcomescompeting risk
spellingShingle Peter M. Ellis
Anand Swaminath
Gregory R. Pond
Patterns of Relapse in Small Cell Lung Cancer: Competing Risks of Thoracic versus CNS Relapse
Current Oncology
small cell lung cancer
recurrent disease
health outcomes
competing risk
title Patterns of Relapse in Small Cell Lung Cancer: Competing Risks of Thoracic versus CNS Relapse
title_full Patterns of Relapse in Small Cell Lung Cancer: Competing Risks of Thoracic versus CNS Relapse
title_fullStr Patterns of Relapse in Small Cell Lung Cancer: Competing Risks of Thoracic versus CNS Relapse
title_full_unstemmed Patterns of Relapse in Small Cell Lung Cancer: Competing Risks of Thoracic versus CNS Relapse
title_short Patterns of Relapse in Small Cell Lung Cancer: Competing Risks of Thoracic versus CNS Relapse
title_sort patterns of relapse in small cell lung cancer competing risks of thoracic versus cns relapse
topic small cell lung cancer
recurrent disease
health outcomes
competing risk
url https://www.mdpi.com/1718-7729/28/4/243
work_keys_str_mv AT petermellis patternsofrelapseinsmallcelllungcancercompetingrisksofthoracicversuscnsrelapse
AT anandswaminath patternsofrelapseinsmallcelllungcancercompetingrisksofthoracicversuscnsrelapse
AT gregoryrpond patternsofrelapseinsmallcelllungcancercompetingrisksofthoracicversuscnsrelapse